Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 145Parkinson Disease 4, Autosomal Dominant Lewy Body 120Melanoma 84Squamous Cell Carcinoma of Head and Neck 56Neoplasms 44Breast Neoplasms 41Stomach Neoplasms 39Colorectal Neoplasms 38Triple Negative Breast Neoplasms 37Neoplasm Metastasis 36Carcinoma, Renal Cell 36Ovarian Neoplasms 30Lung Neoplasms 30Head and Neck Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Transitional Cell 26Carcinoma, Hepatocellular 26Pancreatic Neoplasms 23Esophageal Neoplasms 20Endometrial Neoplasms 16Recurrence 15Prostatic Neoplasms 15Multiple Myeloma 15Fallopian Tube Neoplasms 15Carcinoma 14Sarcoma 13Lymphoma, Large B-Cell, Diffuse 13Small Cell Lung Carcinoma 12Lymphoma, Follicular 12Lymphoma, Non-Hodgkin 11

Interventions

aldesleukin 15Cyclophosphamide 15fludarabine phosphate 12fludarabine 11Interleukin-2 10Nivolumab 6Ipilimumab 6Temozolomide 5pembrolizumab 3Fluorouracil 3trametinib 2sonidegib 2dabrafenib 2binimetinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Sodium Chloride 2Sirolimus 2Radiotherapy 2Radiation 2Peptides 2HhAntag691 2Gefitinib 2Dacarbazine 2Cyclosporine 2Cetuximab 2Capecitabine 2veliparib 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × pembrolizumab × Clear all
NCT04869137 2026-04-08

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
26 enrolled 9 charts
Dermatologic

Skin Neoplasms, Carcinoma, Merkel Cell

NCT02521870 2021-08-03

SYNERGY-001

Dynavax Technologies Corporation

Phase 1/2 Terminated
241 enrolled 23 charts
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Melanoma, Skin Neoplasms

NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡